The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Publication and related bias in meta-analysis
Sterne, J. A. C., Gavaghan, D., & Egger, M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00242-0 · Cited by 2,282
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
Gabizon, A., & Papahadjopoulos, D. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.18.6949 · Cited by 1,131
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
Allavena, P., Sica, A., Solinas, G., Porta, C., & Mantovani, A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.07.004 · Cited by 1,044
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Maeda, H., Fang, J., Inutsuka, T., & Kitamoto, Y. (2003) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00271-0 · Cited by 537
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
Szebeni, J., Muggia, F., Gabizon, A., & Barenholz, Y. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.017 · Cited by 423
Judson, I., Radford, J. A., Harris, M., Blay, J.-Y., van Hoesel, Q., le Cesne, A., van Oosterom, A. T., Clemons, M. J., Kamby, C., Hermans, C., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00050-8 · Cited by 392
Allavena, P., & Mantovani, A. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 384
Evaluation of nanoparticle immunotoxicity
Dobrovolskaia, M. A., Germolec, D. R., & Weaver, J. L. (2009) · Nature Nanotechnology · doi:10.1038/nnano.2009.175 · Cited by 368
Karmali, P. P., & Simberg, D. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.554818 · Cited by 361
Sellers, R. S., Clifford, C. B., Treuting, P. M., & Brayton, C. (2012) · Veterinary Pathology · doi:10.1177/0300985811429314 · Cited by 278
The role of surface charge and hydrophilic groups on liposome clearance in vivo
Gabizon, A., & Papahadjopoulos, D. (1992) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(92)90061-p · Cited by 263
Hong, R. L., Huang, C. J., Tseng, Y., Pang, V. F., Chen, S.-T., Liu, J. J., & Chang, F. (1999) · PubMed · Cited by 227
Stirland, D. L., Nichols, J. W., Miura, S., & Bae, Y. H. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.026 · Cited by 225
Pan, X. Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., & Lee, R. J. (2002) · Blood · doi:10.1182/blood.v100.2.594 · Cited by 200
Clinical Pharmacology of Liposomal Anthracyclines: Focus on Pegylated Liposomal Doxorubicin
Solomon, R., & Gabizon, A. A. (2008) · Clinical Lymphoma and Myeloma · doi:10.3816/clm.2008.n.001 · Cited by 199
Johnson, K. R., Ringland, C., Stokes, B. J., Anthony, D. M., Freemantle, N., Irs, A., Hill, S. R., & Ward, R. L. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70800-2 · Cited by 175
Pastorino, F., Brignole, C., Marimpietri, D., Sapra, P., Moase, E. H., Allen, T. M., & Ponzoni, M. (2003) · PubMed · Cited by 148
Rifkin, R. M., Gregory, S. A., Mohrbacher, A. M., & Hussein, M. A. (2006) · Cancer · doi:10.1002/cncr.21662 · Cited by 130
Stathopoulos, G. P., Antoniou, D., Dimitroulis, J., Michalopoulou, P., Bastas, A., Marosis, K., Stathopoulos, J., Provata, A., Yiamboudakis, P., Veldekis, D., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq234 · Cited by 125
Roy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Immunosuppressive and anti‐inflammatory properties of engineered nanomaterials
Ilinskaya, A. N., & Dobrovolskaia, M. A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12722 · Cited by 118
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
La-Beck, N. M., Zamboni, B. A., Gabizón, A., Schmeeda, H., Amantea, M., Gehrig, P. A., & Zamboni, W. C. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1664-2 · Cited by 118
Self-citationGabizón, A., Isacson, R., Rosengarten, O. S., Tzemach, D., Shmeeda, H., & Sapir, R. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0525-5 · Cited by 110
Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin
Pastorino, F., Paolo, D. D., Piccardi, F., Nico, B., Ribatti, D., Daga, A., Baio, G., Neumaier, C. E., Brignole, C., Loi, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0804 · Cited by 102
Mylonakis, N., Athanasiou, A. E., Ziras, N., Angel, J., Rapti, A., Lampaki, S., Politis, N., Karanikas, C. A., & Kosmas, C. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.017 · Cited by 98
Vascular targeting of doxorubicin using cationic liposomes
Wu, J. H., Lee, A., Lu, Y., & Lee, R. J. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.01.003 · Cited by 97
Anders, C. K., Adamo, B., Karginova, O. A., Deal, A. M., Rawal, S., Darr, D. B., Schorzman, A. N., Santos, C., Bash, R., Kafri, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061359 · Cited by 88
Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth
Moghimi, S. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.051 · Cited by 87
Vail, D. M., Kravis, L. D., Cooley, A. J., Chun, R., & MacEwen, E. G. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050591 · Cited by 87
Hunault, M., Leguay, T., Thomas, X., Legrand, O., Huguet, F., Bonmati, C., Escoffre‐Barbe, M., Legros, L., Turlure, P., Chevallier, P., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.027862 · Cited by 78
Caron, W. P., Lay, J. C., Fong, A. M., La-Beck, N. M., Kumar, P., Newman, S. E., Zhou, H., Monaco, J. H., Clarke‐Pearson, D. L., Brewster, W. R., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208801 · Cited by 71
Self-citationGibson, J., Alzghari, S. K., Ahn, C. W., Trantham, H., & La-Beck, N. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0126 · Cited by 68
Self-citationCabanes, A., Even‐Chen, S., Zimberoff, J., Barenholz, Y., Kedar, E., & Gabizón, A. (1999) · PubMed · Cited by 65
Robert, J. (2006) · Cell Biology and Toxicology · doi:10.1007/s10565-006-0142-9 · Cited by 62
Golan, T., Grenader, T., Ohana, P., Amitay, Y., Shmeeda, H., La-Beck, N. M., Tahover, E., Berger, R., & Gabizón, A. (2015) · Cancer Medicine · doi:10.1002/cam4.491 · Cited by 61
Self-citationSchell, R. F., Sidone, B., Caron, W. P., Walsh, M. D., White, T. F., Zamboni, B. A., Ramanathan, R. K., & Zamboni, W. C. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.07.005 · Cited by 46
Jehn, C., Boulikas, T., Kourvetaris, A., Kofla, G., Possinger, K., & Lüftner, D. (2008) · PubMed · Cited by 31
Jehn, C., Siebmann, S., Pecher, G., Wernicke, K., Possinger, K., & Lüftner, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.6040 · Cited by 27
Kunjachan, S., Jose, S., Thomas, C., Joseph, E., Kiessling, F. M., & Lammers, T. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00955.x · Cited by 18
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Shi, Y., van der Meel, R., Chen, X., & Lammers, T. (2020) · Theranostics · doi:10.7150/thno.49577 · Cited by 868
Mukherjee, A., Waters, A. K., Kalyan, P., Achrol, A. S., Kesari, S., & Yenugonda, V. M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s198353 · Cited by 493
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
Metadata
- Authors
- Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S., & La-Beck, N. M.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 232
- Pages
- 255-264
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2340906166
- Cited by
- 290
- References
- 48
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.